For research use only. Not for therapeutic Use.
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses[1].
BAY-218 (example 23) (72 pM-20 μM) has AHR inhibitory activity with an IC50 of 39.9 μM in in U87 glioblastoma cells[1].?
BAY-218 (1 nM-3 μM) has CYP1A1 inhibitory activity with an IC50 of 70.7 μM in human monocytic U937 cell line[1].?
BAY-218 (1 μM) reverses KA-induced inhibition of TNFα production by LPS stimulated human monocytes[1].
BAY-218 (example 23) (p.o; 30 mg/kg; bid) has good anti-tumor effect combinated with aPD-L1[1].
| Catalog Number | I019111 |
| CAS Number | 2162982-11-6 |
| Synonyms | 6-(4-chlorophenyl)-2-(3-fluorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-3-oxopyridazine-4-carboxamide |
| Molecular Formula | C20H17ClFN3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H17ClFN3O3/c1-12(11-26)23-19(27)17-10-18(13-5-7-14(21)8-6-13)24-25(20(17)28)16-4-2-3-15(22)9-16/h2-10,12,26H,11H2,1H3,(H,23,27)/t12-/m0/s1 |
| InChIKey | RFGRNBWAUZSMBN-LBPRGKRZSA-N |
| SMILES | CC(CO)NC(=O)C1=CC(=NN(C1=O)C2=CC(=CC=C2)F)C3=CC=C(C=C3)Cl |
| Reference | [1]. Norbert Schmees, et al. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides. WO2017202816A1. |
